Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
Posted inCardiology Nephrology news

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.
Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
Posted inCardiology Nephrology news

Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial

The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven by intraglomerular pressure modulation rather than systemic vascular remodeling.
Culturally Tailored Community Health Worker Support Mitigates Interdialytic Weight Gain in Hispanic and Latino Hemodialysis Patients
Posted inNephrology news Public Health

Culturally Tailored Community Health Worker Support Mitigates Interdialytic Weight Gain in Hispanic and Latino Hemodialysis Patients

The Navigate-Kidney trial demonstrates that community health worker support significantly improves interdialytic weight gain, dialysis adherence, and patient activation among Hispanic and Latino individuals on hemodialysis, addressing critical social and clinical barriers in kidney care.
Higher Hospital-Level Utilization of Continuous Kidney Replacement Therapy Associated with Reduced Mortality in Critically Ill Patients
Posted inCritical Care Nephrology news

Higher Hospital-Level Utilization of Continuous Kidney Replacement Therapy Associated with Reduced Mortality in Critically Ill Patients

A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization centers, highlighting a critical volume-outcome relationship in intensive care.
Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
Posted inCardiology Nephrology news Transplantation

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP1RAs to mitigate these chronic complications in the post-transplant population.
Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation
Posted inCritical Care Nephrology news

Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation

This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantly reducing metabolic excursions without delaying acidosis correction.
Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know
Posted inNephrology news

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and quality-of-life differences are uncertain, highlighting the need for individualized decisions and higher-quality research.